Toboroz
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arihiro Kiyosue (principal investigator)
Toboroz
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· 3. fázis· Eli Lilly and Company· Forrás